Razoxane (ICRF 159) in the treatment of psoriasis
- 1 March 1980
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 102 (3) , 307-317
- https://doi.org/10.1111/j.1365-2133.1980.tb08145.x
Abstract
Razoxane (ICRF 159) [(.+-.)1,2-bis(3,5-dioxopiperazin-1-yl)propane], a new anti-mitotic drug, was used in the treatment of 36 patients with severe psoriasis. The drug has proven highly effective both in cutaneous and in arthropathic disease. The drug is well-tolerated by patients and appears to be free of hepatotoxicity. It causes depression of the neutrophil leukocyte count, an effect which is entirely dose-dependent; the hazard to patients can be minimized by careful supervision of therapy.This publication has 13 references indexed in Scilit:
- RAZOXANE (ICRF 159) IN PSORIASISThe Lancet, 1976
- ICRF 159, (±) 1,2-di(3,5-dioxopiperazin-1-yl)propane NSC-129,943; RazoxaneCancer Treatment Reviews, 1976
- The bioavailability in man of ICRF-159 a new oral antineoplastic agentJournal of Pharmacy and Pharmacology, 1975
- Cumulative Cytostatic Effect of ICRF 159Nature, 1974
- An Improved Bacterial Test System for the Detection and Classification of Mutagens and CarcinogensProceedings of the National Academy of Sciences, 1973
- Angiogenesis in Psoriasis: Therapeutic ImplicationsJournal of Investigative Dermatology, 1972
- Metabolic and ultrastructural studies in a patient with pustular psoriasis (von Zumbusch)Archives of Dermatology, 1972
- Methotrexate for psoriasis. A new therapeutic scheduleArchives of Dermatology, 1971
- Mode of Action of the Cytostatic Agent ‘ICRF 159’Nature, 1970
- Control of Malignant Metastases by ICRF 159Nature, 1969